According to Coherent Market Insights, the global memory enhancement drugs market is estimated to be valued at US$ 7,912.1 million in 2022 and is expected to
Daiichi Sankyo and AstraZeneca's ENHERTU also improved progression-free survival by 22 months versus T-DM1 in patients previously treated with HER2 directed therapy in the DESTINY-Breast03 phase
LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) Wednesday announced that ENHERTU, a HER2-directed antibody-drug conjugate or ADC, achieved statistically significant overall survival, reducing the risk
Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Pune, Maharashtra, September 26 2022 (Wiredrelease) Market.Biz –:Breast Cancer Testing Market growth has been analyzed in the research report. This research includes trends, drivers, and restraints that can either transform the market in a positive or detrimental way. This provides information on the potential marke.